IP Library › Granted Patent US 9,248,173
Granted Patent B2
US 9,248,173 · App. 14/706,772 · Granted Feb 2, 2016

WT1 antigen peptide conjugate vaccine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,248,173
App. No.
14/706,772
Granted
Feb 2, 2016
Kind
B2
Abstract

A compound represented by the formula (1): wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2): wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

Claims (101)

1. A method of treating WT1 positive cancer, comprising:

administering a therapeutically effective amount of a pharmaceutical composition to a WT1 positive cancer patient in need thereof, the pharmaceutical composition comprising

a compound selected from the group consisting of

wherein the bond between CR is a bond between the carbonyl group of C and the N-terminal amino group of R, and the bond between C and C is a disulfide bond,

or a pharmaceutically acceptable salt thereof, and

a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.

(SEQ ID NO: 22)

4. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG.

(SEQ ID NO: 24)

5. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.

(SEQ ID NO: 242)

6. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.

(SEQ ID NO: 243)

7. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.

(SEQ ID NO: 244)

8. The method of claim 1 , wherein the WT1 positive cancer is one of leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colorectal cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, urinary bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, and brain tumor.

9. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.

(SEQ ID NO: 22)

10. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG.

(SEQ ID NO: 24)

11. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.

(SEQ ID NO: 242)

12. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.

(SEQ ID NO: 243)

13. The method of claim 1 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.

(SEQ ID NO: 244)

14. The method of claim 1 , wherein the pharmaceutical composition comprises the compound having the formula (4):

or a pharmaceutically acceptable salt thereof.

15. A method of inducing cytotoxic T cells against WT1 positive cancer, comprising:

administering an effective amount of a pharmaceutical composition to a subject, the pharmaceutical composition comprising

a compound selected from the group consisting of

wherein the bond between CR is a bond between the carbonyl group of C and the N-terminal amino group of R, and the bond between C and C is a disulfide bond,

or a pharmaceutically acceptable salt thereof, and

a pharmaceutically acceptable carrier.

16. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

or a pharmaceutically acceptable salt thereof.

17. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.

(SEQ ID NO: 22)

18. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 24).

19. The method of claim 10 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.

(SEQ ID NO: 242)

20. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.

(SEQ ID NO: 243)

21. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (5):

and

a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.

(SEQ ID NO: 244)

22. The method of claim 15 , wherein the WT1 positive cancer is one of leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colorectal cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, urinary bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, and brain tumor.

23. The method of claim 15 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRK.

(SEQ ID NO: 22)

24. The method of claim 15 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CNKRYFKLSHLQMHSRKHTG.

(SEQ ID NO: 24)

25. The method of claim 15 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

CWAPVLDFAPPGASAYGSL.

(SEQ ID NO: 242)

26. The method of claim 15 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSLC.

(SEQ ID NO: 243)

27. The method of claim 15 , wherein the pharmaceutical composition comprises a peptide consisting of an amino acid sequence:

WAPVLDFAPPGASAYGSL.

(SEQ ID NO: 244)

28. The method of claim 15 , wherein the pharmaceutical composition comprises the compound having the formula (4):

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2025
From: SUMITOMO PHARMA CO., LTD.
To: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Reel/Frame 072160/0981 →
CHANGE OF NAME Recorded Jun 10, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060161/0046 →